Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 5, 2000, Pages 1404-1409

  Teede, Helena J ^a   McGrath, Barry P ^a   Smolich, Joseph J ^a   Malan, Erica ^a   Kotsopoulos, Dimitra ^a   Liang, Yu Lu ^a   Peverill, Roger E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Coagulation; Fibrinolysis; Hemostatic markers; Hormone replacement therapy; Thrombosis

Indexed keywords

D DIMER; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; LIPID ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

EID: 0034101946     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.5.1404     Document Type: Article

References (46)

1. Progress in the Management of the Menopause. In: Wren B, ed. New York, NY: Parthenon; 1997.
2. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 1991;164:489-494.
3. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-1049.
4. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199-208.
5. Williams JK, Anthony MS, Honore EK, Herrington DM, Morgan TM. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15:827-836.
6. Clarkeson T, Anthony M, Jerome C. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998;83:721-726.
7. Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of the research protocol. JAMA. 1970;214:1308-1313.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
9. Alexander KP, Newby K, Harrington RA, Peterson ED, Acasas AC, Jett L, Hassleblad V, O'Connor CM, Califf RM, Khan S, Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more angina but less death/MI during follow-up. J Am Coll Cardiol. 1999;33(suppl A):315A. Abstract.
10. Daly E, Vessey MP, Hawkins MM, Carson JL, Cough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
11. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
12. Loscalzo J. Pathogenesis of thrombosis. In: Williams JW, ed. Hematology. 5th ed. New York, NY: McGraw Hill; 1995:1525-1531.
13. Caine YG, Bauer KA, Barzegar S. Ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992;68: 392-395.
14. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 1994;71:420-423.
15. Gebara OCE, Mittelman MA, Walsh BW, Lipinska I, Welly FK, Bellotti G, Muller JE, Sacks FK, Tofler GH. Plasma fibrinolytic inhibitory activity is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidemia. Heart. 1998;80:235-239.
16. Walsh B, Kuller L, Wild R, Paul S, Farmer M, Lawrence J, Shah A, Anderson P. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
17. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, Aznar J, Tortajada M. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol. 1995;173:1849-1854.
18. Koh KK, Mincemoyer R, Minh NB, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon R. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336: 683-690.
19. Pinto S, Bruni V, Rosati D, Frisco D, Costanzo M, Giusti B, Abbate R. Effects of estrogen replacement therapy on thrombin generation. Thromb Res. 1997;85:185-193.
20. Scarabin PY, Alhenc-Gelas M, Plu-Bureau, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomised controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
21. van Wersch JW, Ubachs JM, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem. 1994;32: 449-453.
22. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferneres J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME study: prospective epidemiological study of myocardial infarction. Thromb Haemost. 1998; 80:749-756.
23. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimers, thrombin-antithrombin III complexes and prothrombin fragments F1+2: diagnosis value in clinically suspected deep vein thrombosis. Thromb Haemost. 1991;65:28-32.
24. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
25. Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM, Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 1988;71: 1418-1426.
26. Miller GJ, Bauer KA, Barzegar S, Coper JA, Rosenberg RD. Increased activation of the hemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996;75:767-771.
27. Conard J, Basdevant A, Thomas JL, Ochsenbein E, Denis C, Guyene TT, Degrelle H. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril. 1995;64:957-962.
28. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med. 1993;117:71-77.
29. Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep venous thrombosis. Thromb Haemost. 1995; 74:833-836.
30. Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Donovvan D, McGinnis J, Brill-Edwards P, Panju A, Patel A, Weitz JI. Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism. Thromb Haemost. 1995;75:833-836.
31. Lee LV, Ewald GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol. 1997; 17:628-633.
32. Whitehead M. Progestins and androgens. Fertil Steril. 1994;62: 161s-167s.
33. Levi M, Middeldorp S, Buller HR. Oral contraceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis, which may explain the increased risk of venous thromboembolism. Cardiovasc Res. 1999;41:21-24.
34. Sporrong T, Mattsson L, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 1990;97:939-944.
35. Woodburn KR, Lowe GD. Fibrinogen, fibrin turnover, endothelial products and vascular surgery. Br J Surg. 1997;84:1059-1064.
36. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-76.
37. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Engl J Med. 1985;313:1557-1563.
38. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
39. Winkler UH, Kramer R, Kwee B, Schindler AE. Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens. Zentralbl Gynakol. 1995;117:540-548.
40. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
41. van Beek EJ, van den Ende B, Berckmans RJ, van der Heide YT, Brandjes DP, Sturk A, ten Gate JW. A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism. Thromb Haemost. 1993;70:408-413.
42. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ. Hemostatic markers in acute stroke. Stroke. 1989;20:592-597.
43. Francis CW, Conaghan DG, Scott WI, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation. 1987;75:1170-1177.
44. Lip G, Lowe G. Fibrin D-dimer. a useful clinical marker of thrombogenesis and atherosclerosis. Clin Sci. 1995;89:205-214.
45. Smith FB, Lowe, GD, Fowkes FG, Rumley A, Donnan PT, Housley E. Smoking, hemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis. 1993;102: 155-162.
46. Walsh B, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks F. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.